|
30 January, 2024
|
ICON plc Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call
|
|
|
24 January, 2024
|
New ICON Survey Highlights Importance of Combination Therapies in Future Obesity Treatment
|
|
|
09 January, 2024
|
ICON Issues Financial Guidance for Full Year 2024
|
|
|
08 January, 2024
|
Biotech companies to increase R&D spend but highlight complexity of clinical trials - ICON
|
|
|
04 January, 2024
|
ICON plc to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
|
18 December, 2023
|
ICON Wins Industry Accolades from TIME Magazine, Forbes and Financial Times in Second Half of 2023
|
|
|
07 December, 2023
|
ICON Secures Upgraded Credit Rating from Moody’s Investors Service
|
|
|
08 November, 2023
|
ICON plc to Present at Upcoming Investor Conferences
|
|
|
25 October, 2023
|
ICON Reports Third Quarter 2023 Results
|
|
|
12 October, 2023
|
ICON Secures Upgraded Credit Rating from S&P Global Ratings
|
|
|
21 September, 2023
|
ICON plc Schedules Third Quarter 2023 Earnings Conference Call
|
|
|
20 September, 2023
|
ICON Releases Expanded End-to-end Clinical Trial Tokenisation Solution
|
|
|
13 September, 2023
|
BARDA Partners With ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial
|
|
|
06 September, 2023
|
ICON plc to Present at the Baird Global Healthcare Conference
|
|
|
26 July, 2023
|
ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting
|
|
|
26 July, 2023
|
ICON Reports Second Quarter 2023 Results
|
|
|
13 July, 2023
|
First Half of 2023 Sees ICON Recognised for CRO Excellence, Alongside Industry Awards as an Employer of Choice and for Its Creative and Digital Services
|
|
|
27 June, 2023
|
ICON plc Schedules Second Quarter 2023 Earnings Conference Call
|
|
|
26 June, 2023
|
ICON Releases Latest Version of its Digital Platform, Providing Integrated Patient Services and Harmonised Data in One Platform
|
|
|
26 June, 2023
|
ICON plc Set to Join Russell 3000® Index
|
|
